Compare HTLD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTLD | GERN |
|---|---|---|
| Founded | 1978 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.1M | 808.3M |
| IPO Year | 1995 | N/A |
| Metric | HTLD | GERN |
|---|---|---|
| Price | $14.82 | $1.34 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $11.50 | $2.17 |
| AVG Volume (30 Days) | 660.9K | ★ 14.7M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,709,000.00 | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $8.36 | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $1.04 |
| 52 Week High | $16.64 | $2.01 |
| Indicator | HTLD | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 56.29 |
| Support Level | $14.24 | $1.23 |
| Resistance Level | $16.64 | $1.46 |
| Average True Range (ATR) | 0.52 | 0.08 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 25.22 | 61.43 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.